Dr. Zachary C. Hartman is an Associate Professor at Duke University in the Departments of Surgery, Pathology, and Integrative Immunobiology. He also serves as the Director of the Center for Applied Therapeutics and is a member of the Cellular and Molecular Biology (CMB) and University Program in Genetics and Genomics (UPGG) programs. After earning his undergraduate degree from Northwestern University, he pursued his PhD in the UPGG program at Duke University. After receiving his doctorate in the study of innate immunity and virology, he furthered his research with two post-doctoral fellowships focusing on tumor immunology and breast oncology at Duke University and the MD Anderson Cancer Center.
In 2012, Dr. Hartman returned to Duke to establish a laboratory and research program dedicated to exploring tumor immunology and developing different types of immunotherapeutics. His research encompasses non-viral and viral vaccines, immune checkpoint inhibitors, immune agonists, anti-tumor antibodies, antibody drug conjugates, and strategies to stimulate intratumoral innate and adaptive immune responses. His work has received support from research grants issued by the National Cancer Institute, National Institute for Allergy and Infectious Disease, the Department of Defense, the American Cancer Society, and Susan G. Komen Foundation for the Cure.
Dr. Hartman has garnered recognition for his immuno-oncology research, including awards such as the Paul Calabresi Award for Clinical Oncology, the Jon Shevell Young Scientist Award, an AACR Scholar award as well as support from Susan G. Komen as a recipient of a Career Catalyst Award. Actively involved in professional organizations, Dr. Hartman is a member of AACR, SITC, and AAI, and has served as a member and chair of study sections for organizations such as NIH, DOD, Susan G. Komen, and Cancer UK. He also serves as an associate editor for Cancer Research Communications and special editor for BMC Cancer and Frontiers in Immunology. Additionally, Dr. Hartman is a member of the scientific advisory committee for the Mayo Clinic SPORE. His research output includes 131 manuscripts and abstracts, and he holds 31 international patents. Dr. Hartman’s research has also received sponsorship from several companies, and he is a co-founder of Replicate Biosciences, where he sits on the scientific advisory board.
